TAVR with a self-expanding bioprosthesis was noninferior to surgery for death or disabling stroke at 24 months in low-risk patients with severe aortic stenosis.
Does TAVR with a self-expanding bioprosthesis prevent the composite of death or disabling stroke compared to surgical aortic-valve replacement in patients with severe aortic stenosis at low surgical risk?
In patients with severe aortic stenosis at low surgical risk, TAVR with a self-expanding bioprosthesis was noninferior to surgery for the composite of death or disabling stroke at 24 months.
Absolute Event Rate: 0% vs 0%
In patients with severe aortic stenosis who were at low surgical risk, TAVR with a self-expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite end point of death or disabling stroke at 24 months. (Funded by Medtronic; ClinicalTrials.gov number, NCT02701283.).
“[The study] provides robust, long-term evidence supporting the use of balloon-expandable TAVR in appropriately selected low-risk patients and reinforces the current guideline recommendations.”
Popma et al. (Sat,) reported a other. TAVR with a self-expanding bioprosthesis was noninferior to surgery for death or disabling stroke at 24 months in low-risk patients with severe aortic stenosis.